Sharif Uddin

Takeda (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

8h-index373citations36works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(11), Microscopic Colitis(9), Hormonal Regulation and Hypertension(6), Adrenal Hormones and Disorders(6), Biosimilars and Bioanalytical Methods(5)

Publications36 total

Effect of teduglutide treatment on stool characteristics in children with short bowel syndrome-associated intestinal failure and colon-in-continuity
Intestinal failure.·2025Open Access
Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1
Crohn s & Colitis 360·2023· 2 citedOpen Access
Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome‐Associated Intestinal Failure
Journal of Pediatric Gastroenterology and Nutrition·2023· 7 citedOpen Access
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
Crohn s & Colitis 360·2023· 8 citedOpen Access
Tu1741 EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS STRATIFIED BY ETHNICITY AND RACE: A POOLED ANALYSIS OF DATA FROM GEMINI 1, VARSITY, AND VISIBLE 1
Gastroenterology·2023
P854 Race and ethnicity in ulcerative colitis clinical trial enrolment: a post hoc analysis of patient demographics and clinical characteristics from GEMINI 1, VARSITY, and VISIBLE 1
Journal of Crohn s and Colitis·2023Open Access
P814 Clinical trial design in Crohn’s disease: interpreting future endpoints based on post hoc analyses of the vedolizumab phase 3 trials GEMINI 2 and VISIBLE 2
Journal of Crohn s and Colitis·2023Open Access
P466 Efficacy and safety outcomes in patients with moderate to severe ulcerative colitis stratified by ethnicity and race: a pooled analysis of data from GEMINI 1, VARSITY, and VISIBLE 1
Journal of Crohn s and Colitis·2023Open Access
An App-Based Digit Symbol Substitution Test for Assessment of Cognitive Deficits in Adults With Major Depressive Disorder: Evaluation Study
JMIR Mental Health·2022· 5 citedOpen Access
S983 Baseline Demographics and Disease Characteristics of Patients With Ulcerative Colitis Who Responded to Vedolizumab at Week 6
The American Journal of Gastroenterology·2022
An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis
BMC Nephrology·2022· 2 citedOpen Access
Study on the Migratory and Dweller Birds of Band-Khushdil Khan Lake, Pishin, Pakistan Associated with Population Decline Risk Factors
American Journal of BioScience·2022Open Access
S875 The Evolution of Clinical Trial Design in Ulcerative Colitis: Interpreting Future Endpoints Based on Post-Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1
The American Journal of Gastroenterology·2021
P366 Vedolizumab maintenance therapy reduced use of corticosteroids in patients with Crohn’s disease in the GEMINI 2 trial
Journal of Crohn s and Colitis·2021Open Access
Su565 REAL-WORLD EFFECTIVENESS AND SAFETY OF TEDUGLUTIDE IN ADULT SHORT BOWEL SYNDROME: A META-ANALYSIS
Gastroenterology·2021
Repair of Vesicovaginal FistulA: Experiene of 30 Cases and Analysis of Outcome Predictors
Bangladesh Journal of Urology·2020· 1 citedOpen Access
Intravesical Gemcitabine and Mitomycin C Chemotherapy in the Treatment of Non Muscle Invasive Transitional Cell Carcinoma of Urinary Bladder - a Randommized Clinical Trial
Bangladesh Journal of Urology·2020· 2 citedOpen Access
Sa1880 DOSE ESCALATION OF SUBCUTANEOUS VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: A POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA
Gastroenterology·2020· 2 cited
Sa1879 EFFICACY AND SAFETY OF VEDOLIZUMAB REINITIATION FOLLOWING TREATMENT INTERRUPTION: POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA
Gastroenterology·2020· 1 cited
<p>Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma</p>
Clinical ophthalmology·2020· 9 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Bertil Ekman(6), Claudio Marelli(6), William J. Sandborn(6), Ninfa Candela(5), Karen Lasch(5), Marcus Quinkler(4), Pierre Zelissen(4), Krisztina Kisfalvi(4), Geert D’Haens(4), R Mukherjee(4), Heinrich Achenbach(3), Jingjing Chen(3), Edward V. Loftus(3), Johan Jansson(3), Bruce E. Sands(3), R M Q Khan(3), Robert Murray(2), M.C.J. Verdegem(2), Ragnhildur Bergthorsdottir(2), Pia Burman(2)